Profile
| Metric | Value |
|---|---|
| Full Name | Elanco Animal Health Incorporated |
| Ticker | NYSE: ELAN |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Specialty & Generic Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | elanco.com |
| Employees | 9,000 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $22.52 | |
| Price, 1D Change | -0.49% | |
| Market Cap | $11B | |
| - | ||
| PE Ratio | 308.92 | |
| Beta | 1.28 | |
| Revenue | $4B | |
| Revenue, 1Y Change | +0.50% | |
| EPS | $0.68 | |
| EPS, 1Y Change | +127.18% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $0.68 | |
| EPS Estimate | $0.94 | |
| EPS Est. Change | +38.40% | |
| Revenue | $4.44B | |
| Revenue Estimate | $4.67B | |
| Revenue Est. Change | +5.19% | |
| Current Price | $22.52 | |
| Price Target | - | $25.00 |
| Price Tgt. Change | - | +11.01% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $0.92 | -$2.50 | -371.79% | |
| $0.92 | $0.68 | -25.78% | |
| $0.94 | N/A | +38.40% | |
| $1.04 | N/A | +52.43% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.39B | $4.42B | +0.73% | |
| $4.43B | $4.44B | +0.18% | |
| $4.67B | N/A | +5.19% | |
| $4.93B | N/A | +11.12% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +86.89% | |
| Price, 3Y | +84.29% | |
| Market Cap, 1Y | +87.80% | |
| Market Cap, 3Y | +93.08% | |
| Revenue, 1Y | +0.50% | |
| Revenue, 3Y | -6.82% | |
| EPS, 1Y | +127.18% | |
| EPS, 3Y | +168.56% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $22.52 | |
| SMA 200 | $16.54 | |
| SMA 200 vs Price | -26.56% | |
| SMA 50 | $22.12 | |
| SMA 50 vs Price | -1.77% | |
| Beta | 1.28 | |
| ATR | $0.60 | |
| 14-Day RSI | 55.27 | |
| 10-Day Volatility | 9.12% | |
| 1-Year Volatility | 50.04% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $4.44B | |
| EPS | $0.68 | |
| Gross Profit | $2.44B | |
| Gross Margin | 54.88% | |
| Operating Profit | $251.00M | |
| Operating Margin | 5.65% | |
| Net Income | $338.00M | |
| Net Margin | 7.61% | |
| EBITDA | $1.39B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.73 | |
| Current Ratio | 2.44 | |
| Quick Ratio | 1.25 | |
| - | ||
| F-Score | 7 | |
| Altman Z-Score | 1.54 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 308.92 | |
| PS Ratio | 2.44 | |
| PB Ratio | 1.66 | |
| EV/EBITDA | 16.15 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $6.10B | |
| Cash & Equivalents | $468.00M | |
| Total Assets | $12.61B | |
| Current Assets | $3.22B | |
| Total Liabilities | $6.52B | |
| Current Liabilities | $1.32B | |
| Total Debt | $4.44B | |
| Short Term Debt | $75.00M | |
| Accounts Payable | $296.00M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $4.19B | |
| Operating Expenses | $2.19B | |
| Cost Of Goods Sold | $2.00B | |
| SG&A | $1.31B | |
| D&A | $662.00M | |
| Interest Expense | $0.00 | |
| Income Tax | $150.00M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $541.00M | |
| CFI | $1.16B | |
| CFF | -$1.49B | |
| Capex | $161.00M | |
| Free Cash Flow | $380.00M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Morgan Stanley | → | |
| Barclays | ||
| Keybanc | ||
| UBS | → | |
| UBS | → | |
| JP Morgan | → | |
| Stifel | → | |
| Piper Sandler | → | |
| UBS | → | |
| UBS | → |
Analyst sentiment
Institutional ownership
Screeners with ELAN
Data Sources & References
- ELAN Official Website www.elanco.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1739104/000173910425000071/0001739104-25-000071-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1739104/000173910425000014/0001739104-25-000014-index.htm
- ELAN Profile on Yahoo Finance finance.yahoo.com/quote/ELAN
- ELAN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/elan
FAQ
What is the ticker symbol for Elanco Animal Health Incorporated?
The ticker symbol for Elanco Animal Health Incorporated is NYSE:ELAN
Does Elanco Animal Health Incorporated pay dividends?
No, Elanco Animal Health Incorporated does not pay dividends
What sector is Elanco Animal Health Incorporated in?
Elanco Animal Health Incorporated is in the Healthcare sector
What industry is Elanco Animal Health Incorporated in?
Elanco Animal Health Incorporated is in the Specialty & Generic Drug Manufacturers industry
What country is Elanco Animal Health Incorporated based in?
Elanco Animal Health Incorporated is headquartered in United States
When did Elanco Animal Health Incorporated go public?
Elanco Animal Health Incorporated initial public offering (IPO) was on September 20, 2018
Is Elanco Animal Health Incorporated in the S&P 500?
No, Elanco Animal Health Incorporated is not included in the S&P 500 index
Is Elanco Animal Health Incorporated in the NASDAQ 100?
No, Elanco Animal Health Incorporated is not included in the NASDAQ 100 index
Is Elanco Animal Health Incorporated in the Dow Jones?
No, Elanco Animal Health Incorporated is not included in the Dow Jones index
When was Elanco Animal Health Incorporated last earnings report?
Elanco Animal Health Incorporated's most recent earnings report was on November 5, 2025
When does Elanco Animal Health Incorporated report earnings?
The next expected earnings date for Elanco Animal Health Incorporated is February 25, 2026
